What question did this study set out to answer?

This research aims to evaluate the antimicrobial activity of ceftibuten-avibactam against Enterobacterales from outpatient centers.

January 25, 2026Open Access

Activity of Novel Ceftibuten-Avibactam, Ceftazidime-Avibactam, and Comparators Against a Challenge Set of Enterobacterales from Outpatient Centers and Nursing Homes Across the United States (2022-2024)

Key Points

This research aims to evaluate the antimicrobial activity of ceftibuten-avibactam against Enterobacterales from outpatient centers.
Conducted susceptibility testing on 500 outpatient isolates from 11 US states.
Utilized manual broth microdilution methods for testing effectiveness.
Compared ceftibuten-avibactam with other antibiotics for efficacy assessments.
Ceftibuten showed susceptibility rates of 64% (CLSI) and 23% (EUCAST).
Ceftibuten-avibactam demonstrated 96.4% inhibition at MIC ≤ 1 µg/mL.
Ceftazidime-avibactam achieved a susceptibility rate of 99.6%, highlighting strong effectiveness against resistant strains.

Abstract

Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.

Activity of Novel Ceftibuten-Avibactam, Ceftazidime-Avibactam, and Comparators Against a Challenge Set of Enterobacterales from Outpatient Centers and Nursing Homes Across the United States (2022-2024)

Key Points

Abstract

Cite This Study